Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 22, 2006. The report details a specific corporate action regarding the repurchase of the company's own shares, authorized by shareholders at the Annual General Meeting on May 17, 2006.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 500,000 Ordinary shares of 25 pence each.
- Purchase Price: 1,429.99 pence per share.
- Treasury Shares Held: 190,291,678 shares following the transaction.
- Shares in Issue: 5,794,694,553 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through a buyback program. The company purchased 500,000 shares on August 22, 2006, and intends to hold them in Treasury. No other material changes to operations or financial position are disclosed in this specific filing.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase or subscribe for securities in any jurisdiction.
Key Facts for Investor Verification
- Verify the total cost of the 500,000 share repurchase based on the disclosed price of 1,429.99 pence per share.
- Confirm the updated total share count (5,794,694,553 in issue) against subsequent filings to track dilution or further buybacks.
- Note that the 190,291,678 Treasury shares are excluded from the shares in issue count.
- Recognize that this filing is a transactional report and does not contain quarterly or annual financial performance data.